Publicaciones en colaboración con investigadores/as de Hospital Clinico Universitario de Valencia (76)

2024

  1. Development and validation of an image biomarker to identify metabolic dysfunction associated steatohepatitis: MR–MASH score

    Liver International, Vol. 44, Núm. 1, pp. 202-213

2023

  1. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

    Gastroenterologia y Hepatologia, Vol. 46, Núm. 8, pp. 594-602

2022

  1. Automated Whole-Liver MRI Segmentation to Assess Steatosis and Iron Quantification in Chronic Liver Disease

    Radiology, Vol. 302, Núm. 2, pp. 345-354

  2. Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy

    Scientific Reports, Vol. 12, Núm. 1

  3. Prevalence estimation of significant fibrosis because of NASH in Spain combining transient elastography and histology

    Liver International, Vol. 42, Núm. 8, pp. 1783-1792

2021

  1. Digital pathology enables automated and quantitative assessment of inflammatory activity in patients with chronic liver disease

    Biomolecules, Vol. 11, Núm. 12

  2. Sars-cov-2 vs. Hepatitis virus infection risk in the hemodialysis population: What should we expect?

    International Journal of Environmental Research and Public Health

2020

  1. Epidemiology of hepatitis C virus infection in a country with universal access to direct-acting antiviral agents: Data for designing a cost-effective elimination policy in Spain

    Journal of Viral Hepatitis, Vol. 27, Núm. 4, pp. 360-370

  2. Update on epidemiology of hepatitis B in a low-endemic European country: There is still much to do

    Journal of Viral Hepatitis, Vol. 27, Núm. 11, pp. 1261-1265

2019

  1. Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice-Vie-KinD study

    PLoS ONE, Vol. 14, Núm. 9

2018

  1. Cirrhotic patients with minimal hepatic encephalopathy have increased capacity to eliminate superoxide and peroxynitrite in lymphocytes, associated with cognitive impairment

    Free Radical Research, Vol. 52, Núm. 1, pp. 118-133

  2. Learning and Memory Impairments in Patients with Minimal Hepatic Encephalopathy are Associated with Structural and Functional Connectivity Alterations in Hippocampus

    Scientific Reports, Vol. 8, Núm. 1

  3. Minimal hepatic encephalopathy identifies patients at risk of faster cirrhosis progression

    Journal of Gastroenterology and Hepatology (Australia), Vol. 33, Núm. 3, pp. 718-725

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort

    Journal of Hepatology, Vol. 66, Núm. 6, pp. 1138-1148

  3. Elimination of hepatitis C in Spain: Adaptation of a mathematical model based on the public health strategic plan for addressing hepatitis C in the National Health System

    Medicina Clinica, Vol. 148, Núm. 6, pp. 277-282

  4. Miliary tuberculosis infection during hepatitis C treatment with sofosbuvir and ledipasvir plus ribavirin

    World Journal of Hepatology, Vol. 9, Núm. 3, pp. 161-166

  5. Minimal hepatic encephalopathy is associated with expansion and activation of CD4+CD28-, Th22 and Tfh and B lymphocytes

    Scientific Reports, Vol. 7, Núm. 1

  6. Reduced resting state connectivity and gray matter volume correlate with cognitive impairment in minimal hepatic encephalopathy

    PLoS ONE, Vol. 12, Núm. 10

  7. The PHES battery does not detect all cirrhotic patients with early neurological deficits, which are different in different patients

    PLoS ONE, Vol. 12, Núm. 2